Jump to Main Contents
ncc en

Home > Information > What's New 2023

What's New 2023

Dec. 14, 2023
National Cancer Center Japan and Japan Investment Corporation (JIC) sign agreement to promote comprehensive collaboration
Dec. 13, 2023
Deputy Minister of Health, Saudi Arabia visit
Dec. 12, 2023
National Medical Products Administration (NMPA) visited
Dec. 4, 2023
Delegation from Emilia-Romagna visit
Dec. 1, 2023
Sharing of clinical trial information improves the quality of treatment recommendations by expert panels
Nov. 29, 2023
Molecular Mechanisms of Chromosomal Instability and Anti-Tumor Immune Activation Induced by DNA Replication Stress
Nov. 21, 2023
Researchers from National Cancer Center on ‘Highly Cited Researchers 2023’ List
Nov. 15, 2023
Dr Válek, Deputy Prime Minister and Minister of Health of the Czech Republic visited
Oct. 30, 2023
MoU signed with Chulalongkorn University
Oct. 11, 2023
Romanian Delegation visit
Sep. 22, 2023
Driving Japan-US Collaboration in Oncology
Sep. 20, 2023
Research agreement on CAR-T cancer treatment development concluded between National Cancer Center and Asahi Kasei
Sep. 14, 2023
Our Research Institute is now introduced in the Nature Cancer Index in the 7 September 2023 issue of Nature.
Aug. 21, 2023
Summit confirms trilateral Japan-US-Korea cancer dialogue to expand
Aug. 14, 2023
Carcinogenesis mechanism of gastric cancer discovered with whole genome sequencing
Jul. 21, 2023
International Robotic D2 Gastrectomy Seminar at NCC Hospital East
Jun. 27, 2023
Memorandum of Cooperation on Decentralized Clinical Trials between the Department of Medical Services and the National Cancer Center Japan.
Jun. 26, 2023
Southern Viet Nam Health Commission officials’ visit
Jun. 16, 2023
Bangkok Dusit Medical Services visited NCC
Jun. 12, 2023
Announcing the approval of the apolipoprotein A2 isoform index for in vitro diagnostics in Japan
Jun. 1, 2023
Visit by Stella Kyriakides, European commissioner for Health and Food Safety
May 24, 2023
G7 Cancer is launched
Apr. 19, 2023
World-first confirmation of standard treatment for RAS wild-type colorectal cancer-Paper published in JAMA-
Apr. 12, 2023
Start of Clinical Research of the First Japanese-Produced Next-Generation Photon Counting Computed Tomography
Apr. 10, 2023
Efficacy of Anti-HER2 Therapy with Trastuzumab Deluxecan in Uterine Carcinosarcoma Consistent with PDX-model predictions of efficacy, paving the way for the development of treatments for rare cancers.
Apr. 3, 2023
A clinical trial of Tazemetostat for pediatric and AYA patients with malignant tumors which have no standard treatment or which is refractory to standard treatment using Patient-Proposed Healthcare Service (NCCH2214/ TURTLE trial) to improve drug access for pediatric and AYA patients with refractory tumors.
Mar. 27, 2023
President of National Cancer Center Mongolia Visit
Mar. 14, 2023
World’s Largest Gastric Cancer Genomic Study Reveals Treatment Targets for Japanese Patients Alcohol intake link gives hope for improving prevention strategies
Mar. 9, 2023
President of National Cancer Center Korea Visit
Mar. 9, 2023
French National Cancer Institute(INCa)delegation visited
Mar. 9, 2023
Franco-Japanese Immuno-Oncology Research Workshop
Feb. 28, 2023
Questionable practices identified by an examination of therapeutic plan reviews performed by certified committees under the Act on the Safety of Regenerative Medicine
Jan. 24, 2023
Clinical Utility of Circulating Tumor DNA After Surgery for Colorectal Cancer Demonstrated in a Large-Scale Prospective Study -A Step toward Personalized Postoperative Adjuvant Chemotherapy-
Jan. 5, 2023
Moonshot Research and Development Program ‘Actualization of a cancer-free society through regulation of chronic inflammation’ launched